Results 221 to 230 of about 38,272 (314)

Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. [PDF]

Sci Rep
Dos Santos VA, Viotto ACR, Nascimento MM, Bernardo DRD, Shimizu MHM, de Sena CR, Seguro AC, Volpini RA, de Bragança AC, Canale D.   +9 more
europepmc   +1 more source

Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway

, 2018
Di Yao, Suyu Wang, Min Wang, Weiping Lu
openalex   +2 more sources

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study. [PDF]

Sci Rep
Kim K, Ko SH, Yun JS, Lee KW, Kim ES, Jeong IK, Kim JH, Kim SY, Won KC, Kim M, Cha BS, Kim S, Choi SH, Rhee EJ, Kim SG, Kim BH, Park KS, Ju YC, Heo TW, Ahn YB.   +19 more
europepmc   +1 more source

Efficacy of sacubitril/valsartan combined with dapagliflozin in treating patients with heart failure and diabetes after an acute myocardial infarction

Lifang Zhang, Xiuying Tang, Runjun Li, Jinxia Niu, Jie Gong   +4 more
openalex   +2 more sources

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial

, 2018
Zhaohu Hao, Xiao Huang, Hailin Shao, Fengshi Tian   +3 more
openalex   +2 more sources

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Erande S, Agrawal M, Gulati S, Jagtap N, Kumar NSP, Kapoor VK, Bhushan S, Gadkari R, Jadhav M, Choudhari S, Patil S, Barkate H.   +11 more
europepmc   +1 more source

Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study [PDF]

Chenjie Gu, Xinwei Li, Xianan Guo, Jingying Zhou, Kang Le, Ming Fang   +5 more
openalex   +1 more source

Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD). [PDF]

BMJ Open
Zhang W, Dou Y, Liu J, Liu T, Yan W, Shen Q, Xu H, Zhai Y.   +7 more
europepmc   +1 more source

The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials [PDF]

, 2013

core   +1 more source

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review

Magdalena Kłusek, Katarzyna Chawrylak, Julia Kuszneruk, Maria Kubas, Katarzyna Krzemińska   +4 more
openalex   +2 more sources